Market Overview

Incyte Presents Phase I Trial Results of INCB024360 at ASCO


Incyte Corporation (NASDAQ: INCY) presented final results today from the
Phase I clinical trial for its oral indoleamine dioxygenase-1 (IDO1)
inhibitor, INCB024360, at the American Society of Clinical Oncology
(ASCO) Annual Meeting in Chicago. IDO1 inhibition may provide a new
approach in enhancing the immune system in patients with a variety of
solid tumors.

“IDO1 is an enzyme that works to restrain anti-tumor immunity. When IDO1
is activated in cancer patients with a number of tumor types, their
prognosis is poor. A compound such as INCB024360, which can
significantly inhibit IDO enzyme activity, may remove an important
impediment to an anti-tumor immune response at doses that appear to be
well-tolerated. IDO inhibition provides another immunotherapeutic

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (INCY)

View Comments and Join the Discussion!

Partner Center